Jordan J. Feld, MD; Marc G. Ghany, MD
Feld JJ, Ghany MG. Evolution of Therapy for Chronic Hepatitis B: Progressing from the Simple to the Complex. Ann Intern Med. 2007;147:806-808. doi: 10.7326/0003-4819-147-11-200712040-00014
Download citation file:
Published: Ann Intern Med. 2007;147(11):806-808.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Istanbul University, Cerrahpasa Medical School, Infectious Dis. Dept.
December 20, 2007
More on "Evolution of therapy for chronic hepatitis B: progressing from the simple to the complex"
TO THE EDITOR: We read with great interest the editorial of Feld and Ghany (1). They summarized the complexity of the issue of hepatitis B treatment. They simply compared the response to approved antiviral agents among hepatitis B e antigen-positive patients in the Table. Also they mentioned that response definitions are imperfect. However there are several differences between these studies by many aspects (Table) (1-6). Different methods were used in these studies for detection and quantification HBV DNA. Also sensitivity, detection limit and dynamic range of quantification of these tests make them difficult to compare (7). For example, baseline HBV level which is lower more than 1 log (corresponds to several folds) in adefovir study, for example, makes it almost impossible to compare. Combined data of three studies were given for lamivudine, however virological response criterion differed among these studies. ALT is another issue: Baseline mean ALT levels may not be comparable. Additionally, ALT level as an inclusion criterion varied: greater than 1 time the upper limit of the normal range for pegylated interferon (3), 1.3 times for entecavir (4) and telbivudine (5), and 1.2 times for adefovir (6). Patient numbers, genotype distributions, treatment durations, previous treatment, and probably many other differences exist among the studies compared, discouraging to make a head-to-head comparison. Asian race for example, is associated with poor response to interferon treatment (8), and the rate of this race is highest in pegylated interferon study. Considering the role of high ALT and low DNA on treatment response, a comparison of efficacy of any two drugs should include the details of distribution of these parameters in the study population. Only the telbivudine study described the stratification of the patients according to DNA levels. A simple comparison of several drugs in differing study characteristics may not give robust information to the reader. Unless randomizing the patients in the same study design, it seems difficult to compare the efficacies of any given drugs. When giving such tables, the reader should be warned against the difference among study characteristics and better, the main differences should also be included.
1. Feld JJ, Ghany MG. Evolution of therapy for chronic hepatitis B: progressing from the simple to the complex. Ann Intern Med 2007;147:806-8. [PMID: 18056667]
2. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119:312-23. [PMID: 8328741]
3. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al.; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg- positive chronic hepatitis B. N Engl J Med. 2005;352:2682-95. [PMID: 15987917]
4. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al.; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-10. [PMID: 16525137].
5. Lai CL, Gane E, Liaw YF, Thongsawat S, Wang Y, et al. Telbivudine vs. lamivudine for chronic hepatitis B: first-year results from the international phase III Globe trial [Abstract]. Hepatology. 2005;42:748A.
6. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al.; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-16. [PMID: 12606735]
7. Valsamakis A. Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B. Clin Microbiol Rev. 2007;20:426-39. [PMID: 17630333]
8. Lai CL. Antiviral therapy for hepatitis B and C in Asians. J Gastroenterol Hepatol. 1999;14 Suppl:S19-21. [PMID: 10382633]
Gastroenterology/Hepatology, Infectious Disease, Liver Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only